View in EDS

Adipose-derived mesenchymal stem cell secretome promotes testicular regeneration following chemically induced injury: a review of preclinical studies.

Saved in:
Bibliographic Details
Title: Adipose-derived mesenchymal stem cell secretome promotes testicular regeneration following chemically induced injury: a review of preclinical studies.
Authors: Evangelista, Nadya Nathalia, Shafira, Indah Dian, Sylviana, Nova, Rezano, Andri
Source: Archives of Italian Urology & Andrology / Archivio Italiano di Urologia Andrologia; 2026, Vol. 98 Issue 1, p1-7, 7p
Subject Terms: TESTIS injuries, MESENCHYMAL stem cells, MEDICAL sciences, VASCULAR endothelial growth factors, LEYDIG cells, MALE infertility
Abstract: Introduction: Male infertility is a rising problem globally with male factors contributing up to 50% of all couple infertility cases. The sperm quality decline raises serious concerns regarding future population sustainability and male reproductive health. Adipose-derived mesenchymal stem cell (AdMSC) secretome, defined as a cell-free product comprising paracrine factors secreted by these cells, has emerged as a promising cell-free regenerative therapy for testicular injury, offering advantages of accessibility and therapeutic potential. This systematic review aimed to evaluate the effectiveness of AdMSC secretome in chemically induced testicular injury models. Methods: A systematic literature search was conducted across four electronic databases (PubMed, Google Scholar, OVID and Cochrane) covering publications from 2015 to 2025. Preclinical studies investigating the therapeutic effects of AdMSC secretome in murine models of chemically induced testicular injury were included. Results: Three preclinical studies utilizing male murine models were analysed. Testicular injury was induced using busulfan, doxorubicin or acrylamide. AdMSC secretome was administered via intra-testicular injection (n=2) and intravenous injection (n=1). All studies demonstrated partial regeneration of seminiferous tubule in secretome-treated groups compared with controls. Two studies reported reduced cellular apoptosis using TUNEL assay and acridine orange staining. An increase in Leydig cell numbers was observed following secretome treatment, while Sertoli cells remained unchanged. One study identified vascular endothelial growth factor (VEGF) as a key paracrine mediator, with anti-VEGF intervention abolishing the therapeutic effect. Testosterone levels were consistently higher in secretome-treated groups compared to those receiving AdMSC transplantation. Conclusions: AdMSC secretome demonstrates therapeutic potential in chemically-induced testicular injury by promoting seminiferous tubule regeneration, reducing apoptosis, and enhancing Leydig cell recovery, with VEGF playing a critical mechanistic role. These findings support the potential AdMSC secretome as a cell-free regenerative approach for male infertility. [ABSTRACT FROM AUTHOR]
Copyright of Archives of Italian Urology & Andrology / Archivio Italiano di Urologia Andrologia is the property of PAGEPress and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Description
Abstract:Introduction: Male infertility is a rising problem globally with male factors contributing up to 50% of all couple infertility cases. The sperm quality decline raises serious concerns regarding future population sustainability and male reproductive health. Adipose-derived mesenchymal stem cell (AdMSC) secretome, defined as a cell-free product comprising paracrine factors secreted by these cells, has emerged as a promising cell-free regenerative therapy for testicular injury, offering advantages of accessibility and therapeutic potential. This systematic review aimed to evaluate the effectiveness of AdMSC secretome in chemically induced testicular injury models. Methods: A systematic literature search was conducted across four electronic databases (PubMed, Google Scholar, OVID and Cochrane) covering publications from 2015 to 2025. Preclinical studies investigating the therapeutic effects of AdMSC secretome in murine models of chemically induced testicular injury were included. Results: Three preclinical studies utilizing male murine models were analysed. Testicular injury was induced using busulfan, doxorubicin or acrylamide. AdMSC secretome was administered via intra-testicular injection (n=2) and intravenous injection (n=1). All studies demonstrated partial regeneration of seminiferous tubule in secretome-treated groups compared with controls. Two studies reported reduced cellular apoptosis using TUNEL assay and acridine orange staining. An increase in Leydig cell numbers was observed following secretome treatment, while Sertoli cells remained unchanged. One study identified vascular endothelial growth factor (VEGF) as a key paracrine mediator, with anti-VEGF intervention abolishing the therapeutic effect. Testosterone levels were consistently higher in secretome-treated groups compared to those receiving AdMSC transplantation. Conclusions: AdMSC secretome demonstrates therapeutic potential in chemically-induced testicular injury by promoting seminiferous tubule regeneration, reducing apoptosis, and enhancing Leydig cell recovery, with VEGF playing a critical mechanistic role. These findings support the potential AdMSC secretome as a cell-free regenerative approach for male infertility. [ABSTRACT FROM AUTHOR]
ISSN:11243562
DOI:10.4081/aiua.2026.14735